Trade Ideas
Actionable trade ideas with entry/stop/target and risk framing.
Sumitomo Mitsui (SMFG) - Buy the Semiconductor Upside; Trade Plan Included
ADR near 52-week high but dividend traction and semiconductor financing exposure justify a tactical 'buy' with defined risk limits
Sumitomo Mitsui Financial Group (SMFG) is a buy here on a tactical basis. The ADR is trading near its 52-week high as the market prices a recovery in ...
CleanSpark: Cheap Relative to Asset Base, Levered to Bitcoin Upside and AI Data-center Optionality
A high-conviction long swing with tight risk controls — buy for upside to $22 if Bitcoin and AI demand continue to accelerate
CleanSpark (CLSK) looks materially undervalued on a simple asset/equity basis and is posting an earnings inflection driven by higher mining realizatio...
U.S. Gold Corp. (USAU): Buyable Developer with Permitted Projects — Tactical Long for 2026
No.4 in our Top 5 Mining Stocks to Watch in 2026 — trade idea with entry, stop and targets
U.S. Gold Corp. (USAU) is a small-cap US-focused gold developer with permitted, derisked assets in Wyoming, Nevada and Idaho. The company carries mode...
Bankwell (BWFG) - Cheap, Profitable Regional Bank with Room to Run Into 2026
Solid quarterly momentum, attractive P/B and P/E, and a dependable dividend make BWFG a tactical long into 2026 — target: $65
Bankwell Financial has shown steady sequential earnings growth through 2025, a capital-light balance sheet with roughly $3.24B in assets and ~$293M in...
Blackstone: Fee Engine Catching Up as the Deal Pipeline Reopens
A tactical long into BX as fee-bearing AUM scales, operating cash flow stays healthy and capital returns continue to support the yield
Blackstone sits at an inflection where its $906.2B of fee-earning AUM and scale across private equity, real estate and private credit are starting to ...
Magnolia Oil & Gas (MGY) - Cash-Flowed, Unhedged Oil Growth with a Defensive Tilt
A measured long idea: buy the dip for income + growth, size for oil-price risk
Magnolia (MGY) is a cash-generative Eagle Ford pure-play with consistent quarterly operating cash flow and a conservative balance sheet. The company i...
PrimeEnergy (PNRG) - A Clean Balance Sheet, Cash Flow-Driven Long Idea
No explicit long-term debt on the books and strong operating cash flow make a tactical long — buy on dips, trim into strength.
PrimeEnergy Resources (PNRG) is a small independent oil and gas producer with a surprisingly clean balance sheet and recurring operating cash flow. Re...
Datadog: AI Momentum + Strong Cash Flow — a Tactical Long with Asymmetric Upside
Platform-level observability, growing AI hooks, and improving profitability make DDOG a pragmatic growth trade at current levels
Datadog's core observability business is healthy (Q3 FY2025 revenue $885.7M, sequential acceleration) and the company is converting AI interest into p...
Nova Ltd. (NVMI): Agnostic AI Winner Laying the Groundwork for a Cash-Generating Run
Metrology plays quiet but pivotal role in the AI chip cycle — NVMI looks positioned to monetize agnostic demand into durable cash flow.
Nova Ltd. is a niche metrology equipment supplier whose product set is used across advanced semiconductor processes. With a majority of revenue tied t...
AbbVie: Buy the Long-Term Story, Respect Near-Term Volatility
Strong cash flow and a deep immunology/oncology roster offset booking shocks and policy risk - trade with a plan.
AbbVie is facing an earnings trough driven by elevated operating charges and integration costs, but the core cash engine remains intact. Use a staged ...
Buy GHRS into IND Decision - GH001 Data Momentum, Binary Risk
GH Research is trading on clinical momentum for GH001 ahead of an upcoming FDA IND decision; risk-adjusted long with tight stop.
GH Research (GHRS) has delivered a string of program updates for GH001 and appears to be approaching a regulatory inflection point after submitting an...
Buy the Blind-Side Dip in Corcept (CORT): Relacorilant Is Salvageable, Balance Sheet Is the Safety Net
FDA Complete Response Letter knocked the stock; fundamentals and cash cushion make a disciplined long worthwhile for patient, risk-aware investors.
Corcept Therapeutics sold off sharply after an unexpected FDA Complete Response Letter on relacorilant, but its commercial revenue runway, recent prof...